Abstract
Multisystem Inflammatory Syndrome (MIS) is a severe medical condition that can develop following a COVID-19 infection. It is characterized by widespread tissue inflammation, affecting various organs such as the heart, lungs, kidneys, brain, skin, eyes, and gastrointestinal system. A new medical condition emerged in children during the early stages of the COVID-19 pandemic. This condition necessitated intensive care due to symptoms like fever, abdominal pain, heart failure, and shock, which could lead to fatal outcomes. This condition bore some similarities to Kawasaki disease and was named ‘Multisystemic Inflammatory Syndrome in Children (MIS-C)’ by the Centers for Disease Control and Prevention (CDC) in April 2020. Subsequently, similar clinical conditions were reported in adults in June 2020, and this condition in adults was defined as ‘MIS-A.’ MIS-A primarily affects individuals aged 21 and older. It is characterized by persistent fever, multi-organ involvement, elevated markers of systemic inflammation, a history of exposure to SARS-CoV-2, and the absence of an alternative diagnosis. Early diagnosis of MIS-A is crucial, as a delayed diagnosis can be life-threatening.